Biocon unit gets USFDA nod for genetic anti-bacterial drug
Biocon on Tuesday said its unit in partnership with Carnegie Pharmaceuticals LLC has received approval from the US health regulator for a genetic anti-bacterial medication. Biocon Pharma, a wholly-owned subsidiary of the company, in partnership with Carnegie, has received tentative approval from the US Food and Drug Administration (USFDA) for the ANDA for Rifaximin Tablets,…